PD-1治疗晚期原发性肝癌患者的安全性及临床疗效观察

王毅欣; 胡宗涛; 张永康; 曾平; 王宏志

doi:10.3971/j.issn.1000-8578.2020.19.1112

PD-1治疗晚期原发性肝癌患者的安全性及临床疗效观察

Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma

摘要

摘要:
目的观察PD-1治疗晚期肝癌患者的近期临床疗效及总生存期。
方法回顾性分析48例PD-1（观察组）治疗及55例甲磺酸阿帕替尼（对照组）治疗晚期肝癌患者的临床资料，分析患者近期临床疗效、总生存期和不良反应。
结果观察组AFP、ALT、AST、ECOG、Child-Paugh评分、客观缓解率及疾病控制率优于对照组（P < 0.05），且观察组患者的生存期（95%CI: 7.24~8.64月）明显高于对照组（95%CI: 5.13~6.39月）（P < 0.05）。两组间皮疹、恶心呕吐及高血压不良反应差异有统计学意义（P < 0.05）。
结论 PD-1较甲磺酸阿帕替尼可改善晚期肝癌患者近期临床疗效及延长晚期肝癌患者总生存期。

Abstract:
Objective To observe the short-term clinical effect and total survival of advanced hepatocellular carcinoma patients treated with PD-1.
Methods We retrospectively analyzed the clinical data of 48 patients with advanced hepatocellular carcinoma treated with PD-1 monoclonal antibody (observation group) and 55 patients with advanced hepatocellular carcinoma treated with apatinib mesylate(control group). Short-term clinical effect, overall survival and adverse reactions were analyzed.
Results The AFP, ALT, AST, ECOG, Child-Paugh score, objective remission rate and disease control rate in the observation group were better than those in the control group (P < 0.05), and the overall survival in the observation group (95%CI: 7.24-8.64 months) was significantly longer than that in the control group (95%CI: 5.13-6.39 months) (P < 0.05). There were significant differences in rashes, nausea, vomiting and adverse reactions of hypertension between two groups (P < 0.05).
Conclusion Compared with apatinib mesylate, PD-1 could improve the short-term clinical efficacy and prolong the overall survival of patients with advanced hepatocellular carcinoma.

HTML全文

参考文献(20)

施引文献

资源附件(0)